| The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. | |
| | |
MedLine Citation:
|
PMID: 19088184 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The study was set up to determine the clinical value of dihydroxyphenylalanine positron emission tomography-computed tomography ([(18)F]DOPA PET-CT) in patients with neuroendocrine tumors (NETs). Eighty-two patients with suspected/known NET were imaged with PET(-CT) using [(18)F]DOPA. Patients were divided into two groups: primary diagnosis/staging and restaging of disease. All patients without previous diagnosis of NET had biochemical proof of disease. The diagnostic accuracy of PET was assessed by comparing the histopathology and clinical follow-up. The overall accuracy of [(18)F]DOPA PET was 90%. In patients having PET for primary diagnosis/staging (n=32), the accuracy of PET was 88%, and for restaging 92% (n=61). The mean s.d. sizes of primary and metastatic lesions detected by PET were 26+/-11 and 16+/-9 mm respectively. In organ-region-specific analysis, the sensitivity and specificity were 100% in the primary diagnosis of pheochromocytoma (n=16) and metastases were found in all cases with recurrent disease (n=5). The accuracy for NET of gastrointestinal tract was 92% in restaging (n=24). For the NETs located in the head-neck-thoracic region (n=19), the overall accuracy of PET was 89% including 12 cases of recurrent medullary thyroid cancer with a sensitivity of 90%. In analysis of patients with biochemical proof of disease combined with negative conventional imaging methods, PET had positive and negative predictive value of 92% and 95% respectively. [(18)F]DOPA PET-CT provided important additional information in the diagnosis of pheochromocytoma and restaging of known NET. Both in primary diagnosis and in patients with formerly known NET and increasing tumor markers, [(18)F]DOPA PET-CT is a sensitive first-line imaging method. |
| | |
Authors:
|
Saila Kauhanen; Marko Seppänen; Jari Ovaska; Heikki Minn; Jörgen Bergman; Pirkko Korsoff; Pasi Salmela; Juha Saltevo; Timo Sane; Matti Välimäki; Pirjo Nuutila |
Related Documents
:
|
1523304 - Immunoscintigraphy performed with in-111-labeled cyt-103 in the management of colorecta... 11169064 - 18f-fluorodeoxyglucose (fdg)-pet features of focal nodular hyperplasia (fnh) of the liver. 18310274 - Bone metastases from differentiated thyroid carcinoma. 11079584 - Whole-body fdg positron emission tomographic imaging for staging esophageal cancer comp... 20831824 - Case report of mr perfusion imaging in sinking skin flap syndrome: growing evidence for... 3878784 - Significance of extrapancreatic findings in computed tomography (ct) of acute pancreati... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies Date: 2008-12-16 |
Journal Detail:
|
Title: Endocrine-related cancer Volume: 16 ISSN: 1351-0088 ISO Abbreviation: Endocr. Relat. Cancer Publication Date: 2009 Mar |
Date Detail:
|
Created Date: 2009-02-27 Completed Date: 2009-05-11 Revised Date: 2009-06-29 |
Medline Journal Info:
|
Nlm Unique ID: 9436481 Medline TA: Endocr Relat Cancer Country: England |
Other Details:
|
Languages: eng Pagination: 255-65 Citation Subset: IM |
Affiliation:
|
Turku PET Center, Turku University Central Hospital, FIN-20521 Turku, Finland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Gland Neoplasms
/
pathology,
radionuclide imaging Adult Carcinoma, Medullary / pathology, radionuclide imaging False Negative Reactions False Positive Reactions Female Fluorodeoxyglucose F18 / diagnostic use* Gastrointestinal Neoplasms / pathology, radionuclide imaging Humans Male Middle Aged Neoplasm Staging / methods* Neuroendocrine Tumors / pathology*, radionuclide imaging* Pheochromocytoma / pathology, radionuclide imaging Positron-Emission Tomography / methods*, standards Radiopharmaceuticals / diagnostic use Reproducibility of Results Sensitivity and Specificity Thyroid Neoplasms / pathology, radionuclide imaging |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
| Comments/Corrections | |
Erratum In:
|
Endocr Relat Cancer. 2009 Jun;16(2):661 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mitochondrial dysfunction in mut methylmalonic acidemia.
Next Document: Genome-wide analysis of cancer/testis gene expression.